Houston nonprofit tests Comcast's new vision control technology for viewers with disabilities

tech for good

The Easter Seals of Houston demonstrated new vision control technology from Comcast. Photo courtesy of Easter Seals

A local nonprofit organization has tapped into new technology from Comcast to benefit the community of people with visual disabilities and impairments.

In November 2014, the company announced the industry's first voice-enabled television user interface, a solution that allowed those who are blind or visually impaired to navigate the platform. In May 2015, Comcast announced the Xfinity remote with voice control. Later that same year, the company produced the first live entertainment show in U.S. broadcast history to be accessible to people with visual disabilities.

Continuing on this track of innovation, in June 2019, the company announced eye control for television. Any Xfinity user can now change the channel, set a recording, and search for a show using eye movement, working seamlessly with existing eye gaze hardware and software.

The Easter Seals Greater Houston demonstrated the new technology with their community, posted on the its YouTube page. The demonstration showcased the web-based remote for tablets and computers that pairs with an eye gaze system allowing viewers to control their smart TV.

"While eye gaze technology has existed for quite some time, last summer Comcast launched the Xfinity X1 eye control, which is a web-based TV remote for tablets and computers that pairs with an existing eye gaze system," says Cristen Reat, founder and program director of Easter Seals' BridgingApps. "This feature allows people with physical disabilities, such as Cerebral Palsy, ALS, and spinal cord injuries the ability to change the channel, set a recording and search for a favorite TV show with just their eyes."

Reat tells InnovationMap that most people who have significant physical disabilities are also nonverbal or have nonstandard speech, making a voice remote not a possibility.

"Now, with this new feature, they can do things without relying on a caregiver," says Reat.

The Comcast website states that X1 eye control is free and uses a web page remote control that works seamlessly with existing eye gaze hardware and software, Sip-and-Puff switches, and other existing assistive technologies. To use eye control, Xfinity customers can visit xfin.tv/access and use their Xfinity login credentials to pair the web-based remote with their set-top-box. Then, each time the customer gazes at a button, the web-based remote will send the corresponding command to the television.

"The response from clients we have demonstrated this with has been ecstatic," says Reat. "Something as simple as being able to change the channel independently, without relying on another person's help, can be life-changing."

Reat tells InnovationMap that Comcast and Easter Seals have collaborated in the past.

"We've been great partners, especially over the past few years," says Reat. "Because of that partnership, they reached out to us when they wanted to create awareness about this new feature."

"Changing the channel on a TV is something most of us take for granted but until now, it was a near-impossible task for millions of viewers," says Tom Wlodkowski, vice president of accessibility at Comcast in the product launch news release. "When you make a product more inclusive you create a better experience for everyone and we're hoping our new X1 feature makes a real difference in the lives of our customers."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston hospital names leading cancer scientist as new academic head

new hire

Houston Methodist Academic Institute has named cancer clinician and scientist Dr. Jenny Chang as its new executive vice president, president, CEO, and chief academic officer.

Chang was selected following a national search and will succeed Dr. H. Dirk Sostman, who will retire in February after 20 years of leadership. Chang is the director of the Houston Methodist Dr. Mary and Ron Neal Cancer Center and the Emily Herrmann Presidential Distinguished Chair in Cancer Research. She has been with Houston Methodist for 15 years.

Over the last five years, Chang has served as the institute’s chief clinical science officer and is credited with strengthening cancer clinical trials. Her work has focused on therapy-resistant cancer stem cells and their treatment, particularly relating to breast cancer.

Her work has generated more than $35 million in funding for Houston Methodist from organizations like the National Institutes of Health and the National Cancer Institute, according to the health care system. In 2021, Dr. Mary Neal and her husband Ron Neal, whom the cancer center is now named after, donated $25 million to support her and her team’s research on advanced cancer therapy.

In her new role, Chang will work to expand clinical and translational research and education across Houston Methodist in digital health, robotics and bioengineered therapeutics.

“Dr. Chang’s dedication to Houston Methodist is unparalleled,” Dr. Marc L. Boom, Houston Methodist president and CEO, said in a news release. “She is committed to our mission and to helping our patients, and her clinical expertise, research innovation and health care leadership make her the ideal choice for leading our academic mission into an exciting new chapter.”

Chang is a member of the American Association of Cancer Research (AACR) Stand Up to Cancer Scientific Advisory Council. She earned her medical degree from Cambridge University in England and completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research. She earned her research doctorate from the University of London.

She is also a professor at Weill Cornell Medical School, which is affiliated with the Houston Methodist Academic Institute.

Texas A&M awarded $1.3M federal grant to develop clean energy tech from electronic waste

seeing green

Texas A&M University in College Station has received a nearly $1.3 million federal grant for development of clean energy technology.

The university will use the $1,280,553 grant from the U.S. Department of Energy to develop a cost-effective, sustainable method for extracting rare earth elements from electronic waste.

Rare earth elements (REEs) are a set of 17 metallic elements.

“REEs are essential components of more than 200 products, especially high-tech consumer products, such as cellular telephones, computer hard drives, electric and hybrid vehicles, and flat-screen monitors and televisions,” according to the Eos news website.

REEs also are found in defense equipment and technology such as electronic displays, guidance systems, lasers, and radar and sonar systems, says Eos.

The grant awarded to Texas A&M was among $17 million in DOE grants given to 14 projects that seek to accelerate innovation in the critical materials sector. The federal Energy Act of 2020 defines a critical material — such as aluminum, cobalt, copper, lithium, magnesium, nickel, and platinum — as a substance that faces a high risk of supply chain disruption and “serves an essential function” in the energy sector.

“DOE is helping reduce the nation’s dependence on foreign supply chains through innovative solutions that will tap domestic sources of the critical materials needed for next-generation technologies,” says U.S. Energy Secretary Jennifer Granholm. “These investments — part of our industrial strategy — will keep America’s growing manufacturing industry competitive while delivering economic benefits to communities nationwide.”

------

This article originally appeared on EnergyCapital.

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”

View All Listings